Tatum Anderson of IP Watch has run a story on the various challenges against the tenofovir patents in India and the potential impact in Brazil. Notably, an interview with a Gilead spokesman reveals:
“If Gilead does not gain patents in India we would not enforce our agreements with the Indian generic companies.”
However, Gilead claims it has patents in middle-income countries which would prevent the Indian companies from importing generic versions there. It would be interesting to know which of the middle-income countries Gilead has filed and secured patents in. Readers may be aware from an earlier post that following our searches in South Africa, we were surprised to learn that Gilead did not have any patent rights on tenofovir.